title: Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
abstract: Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.
authors.affiliation: Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Bornova, Izmir, Turkey.
authors.forename: B
authors.initials: B
authors.lastname: Karabulut
authors.forename: C
authors.initials: C
authors.lastname: Erten
authors.forename: M K
authors.initials: MK
authors.lastname: Gul
authors.forename: E
authors.initials: E
authors.lastname: Cengiz
authors.forename: B
authors.initials: B
authors.lastname: Karaca
authors.forename: Y
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: G
authors.initials: G
authors.lastname: Gorumlu
authors.forename: H
authors.initials: H
authors.lastname: Atmaca
authors.forename: S
authors.initials: S
authors.lastname: Uzunoglu
authors.forename: U A
authors.initials: UA
authors.lastname: Sanli
authors.forename: Y
authors.initials: Y
authors.lastname: Baran
authors.forename: R
authors.initials: R
authors.lastname: Uslu
mesh_terms: D000728:Androgens / Q000502:physiology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis; D053148:Caspase 3 / Q000378:metabolism; D053179:Caspase 7 / Q000378:metabolism; D045744:Cell Line, Tumor; D053938:DNA Fragmentation / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D000077143:Docetaxel; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D043823:Taxoids / Q000494:pharmacology* / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D000728:Androgens; D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D019253:Proto-Oncogene Proteins c-bcl-2; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid; D053148:Caspase 3; D053179:Caspase 7